Target RWE announces launch of 35 new observational disease state registries and milestone in TARGET-DERM registry

Target RWE has issued a press release explaining two new developments in its disease state registries, including the launch of 35 new registries in multiple indication and milestone in the TARGET-DERM registry.

Target RWE, one of the largest providers of real-world evidence (RWE) in non-cancer conditions, has recently announced the launch of 35 registries in a range of high unmet need conditions that will continuously capture real-world data (RWD), natural history data and patient outcomes. Across registries such as TARGET-NEURO, TARGET-METABOLIC and TARGET-AUTOIMMUNE, Target RWE will gather patient feedback through digital surveys (patient-reported outcome measures) and collect whole blood, plasma, serum, and tissue samples for its exclusive biorepository. These registries will help deliver meaningful disease insights into these disease communities to allow stakeholders to generate and analyze RWD for healthcare decisions and inform drug development and RWE initiatives.

Commenting on the announcement Michael W. Fried, M.D., FAASLD, Co-Founder and Chief Medical Officer of Target RWE said “When bringing advanced analytics together with real-world data, it is imperative to be able to look across communities to draw strong conclusions. ….. We are thrilled to launch an impressive number of new disease state registries today and we look forward to continuing to produce fit-for-purpose data that address diseases that pose a significant public health burden”.

Target RWE is the only RWE company with a biorepository of tissue samples that can be studied as part of larger groups. The biorepository enables Target RWE to combine comprehensive biomarker, translational, and genomic data with its established research communities.

In announcing the new disease-state registries, Targets RWE also confirmed more than 10,000 tissue samples had been acquired as part of this its TARGET-DERM registry. Launched in 2019, the TARGET-DERM registry collects data on the health and outcomes for adult and pediatric patients with atopic dermatitis and other immune-mediated inflammatory skin conditions, such as psoriasis, who are being treated in their usual academic and community clinical settings.

“The high-quality longitudinal data in TARGET-DERM is moving the field forward and providing key details on real-world impact. The registry is well-positioned to capture the use of new therapies in both the academic and community setting,” explained Emma Guttman-Yassky, M.D., PhD, of Icahn School of Medicine at Mount Sinai and Steering Committee Co-Chair of TARGET-DERM.

 

Source: